Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases $81,292.79 in Stock

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi purchased 83,807 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was acquired at an average price of $0.97 per share, for a total transaction of $81,292.79. Following the transaction, the chief executive officer owned 4,556,068 shares of the company’s stock, valued at $4,419,385.96. The trade was a 1.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ivor Elrifi also recently made the following trade(s):

• On Wednesday, August 5th, Ivor Elrifi purchased 237,616 shares of Tiziana Life Sciences stock. The stock was bought at an average cost of $1.00 per share, for a total transaction of $237,616.00.
• On Monday, August 3rd, Ivor Elrifi acquired 667,000 shares of Tiziana Life Sciences stock. The shares were bought at an average price of $1.00 per share, with a total value of $667,000.00.

Tiziana Life Sciences Price Performance

TLSA opened at $1.00 on Friday. The business has a fifty day simple moving average of $1.13 and a 200-day simple moving average of $1.30. Tiziana Life Sciences Ltd has a fifty-two week low of $0.87 and a fifty-two week high of $2.53.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Weiss Ratings lowered Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Zacks Research raised shares of Tiziana Life Sciences to a “hold” rating in a research note on Tuesday, July 14th. Finally, Wall Street Zen cut shares of Tiziana Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce”.

Institutional Trading of Tiziana Life Sciences

Several large investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new stake in shares of Tiziana Life Sciences in the third quarter valued at $520,000. Jane Street Group LLC grew its holdings in shares of Tiziana Life Sciences by 968.2% during the first quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock valued at $181,000 after buying an additional 151,858 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Tiziana Life Sciences by 413.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock valued at $164,000 after buying an additional 88,830 shares in the last quarter. Bison Wealth LLC acquired a new position in Tiziana Life Sciences during the fourth quarter valued at $30,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Tiziana Life Sciences during the fourth quarter valued at $59,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.